These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34322651)

  • 1. Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk.
    Idos GE; Kurian AW; Ricker C; Sturgeon D; Culver JO; Kingham KE; Koff R; Chun NM; Rowe-Teeter C; Lebensohn AP; Levonian P; Lowstuter K; Partynski K; Hong C; Mills MA; Petrovchich I; Ma CS; Hartman AR; Allen B; Wenstrup RJ; Lancaster JM; Brown K; Kidd J; Evans B; Mukherjee B; McDonnell KJ; Ladabaum U; Ford JM; Gruber SB
    JCO Precis Oncol; 2019 Mar; 3():. PubMed ID: 34322651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.
    Culver JO; Ricker CN; Bonner J; Kidd J; Sturgeon D; Hodan R; Kingham K; Lowstuter K; Chun NM; Lebensohn AP; Rowe-Teeter C; Levonian P; Partynski K; Lara-Otero K; Hong C; Morales Pichardo J; Mills MA; Brown K; Lerman C; Ladabaum U; McDonnell KJ; Ford JM; Gruber SB; Kurian AW; Idos GE
    Cancer; 2021 Apr; 127(8):1275-1285. PubMed ID: 33320347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Universal Genetic Testing vs. Guideline-Directed Testing for Hereditary Cancer Syndromes Among Traditionally Underrepresented Patients in a Community Oncology Program.
    Jones JC; Golafshar MA; Coston TW; Rao R; Wysokinska E; Johnson E; Esplin ED; Nussbaum RL; Heald B; Klint M; Barrus K; Uson PL; Nguyen CC; Colon-Otero G; Bekaii-Saab TS; Dronca R; Kunze KL; Samadder NJ
    Cureus; 2023 Apr; 15(4):e37428. PubMed ID: 37181954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Informing models of cancer genetics care in the era of multigene panel testing with patient-led recommendations.
    Underhill-Blazey M; Blonquist T; Chittenden A; Pozzar R; Nayak M; Lansang K; Hong F; Garber J; Stopfer JE
    J Genet Couns; 2021 Feb; 30(1):268-282. PubMed ID: 32851753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer.
    Coughlin SE; Heald B; Clark DF; Nielsen SM; Hatchell KE; Esplin ED; Katona BW
    JCO Precis Oncol; 2022 Nov; 6():e2200517. PubMed ID: 36370464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Family communication of cancer genetic test results in an ethnically diverse population: a qualitative exploration of more than 200 patients.
    Hodan R; Picus M; Stanclift C; Ormond KE; Pichardo JM; Kurian AW; Ricker C; Idos GE
    J Community Genet; 2024 Aug; 15(4):363-374. PubMed ID: 38814439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program.
    Hermel DJ; McKinnon WC; Wood ME; Greenblatt MS
    Fam Cancer; 2017 Jan; 16(1):159-166. PubMed ID: 27401692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data.
    van Marcke C; Collard A; Vikkula M; Duhoux FP
    Crit Rev Oncol Hematol; 2018 Dec; 132():138-144. PubMed ID: 30447919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients' Medical and Psychosocial Experiences After Detection of a
    Hamilton JG; Long JM; Brandt AC; Brower J; Symecko H; Salo-Mullen EE; Christian SN; Harstad T; Couch FJ; Garber JE; Offit K; Robson ME; Domchek SM
    JCO Precis Oncol; 2019; 3():. PubMed ID: 31511843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment and Validation of a Phenotype-Enhanced Variant Classification Framework to Promote or Demote RYR2 Missense Variants of Uncertain Significance.
    Giudicessi JR; Lieve KVV; Rohatgi RK; Koca F; Tester DJ; van der Werf C; Martijn Bos J; Wilde AAM; Ackerman MJ
    Circ Genom Precis Med; 2019 May; 12(5):e002510. PubMed ID: 31112425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
    Chang J; Seng S; Yoo J; Equivel P; Lum SS
    Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of Variants of Uncertain Significance Among Patients With Breast Cancer Undergoing Genetic Testing: Regional Perspectives.
    Abdel-Razeq H; Tamimi F; Abujamous L; Abdel-Razeq R; Abunasser M; Edaily S; Abdulelah H; Khashabeh RA; Bater R
    Front Oncol; 2022; 12():673094. PubMed ID: 35402282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center.
    Tatineni S; Tarockoff M; Abdallah N; Purrington KS; Assad H; Reagle R; Petrucelli N; Simon MS
    Cancer Med; 2022 Mar; 11(6):1465-1473. PubMed ID: 35040284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychological distress following multi-gene panel testing for hereditary breast and ovarian cancer risk.
    Carlsson L; Bedard PL; Kim RH; Metcalfe K
    J Genet Couns; 2024 Jul; ():. PubMed ID: 39044246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a 27-gene inherited cancer panel across 630 consecutive patients referred for testing in a clinical diagnostic laboratory.
    Gardner SA; Weymouth KS; Kelly WS; Bogdanova E; Chen W; Lupu D; Suhl J; Zeng Q; Geigenmüller U; Boles D; Okamoto PM; McDowell G; Hayden MA; Nagan N
    Hered Cancer Clin Pract; 2018; 16():1. PubMed ID: 29308099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic testing for hereditary hyperparathyroidism and familial hypocalciuric hypercalcaemia in a large UK cohort.
    Mariathasan S; Andrews KA; Thompson E; Challis BG; Wilcox S; Pierce H; Hale J; Spiden S; Fuller G; Simpson HL; Fish B; Jani P; Seetho I; Armstrong R; Izatt L; Joshi M; Velusamy A; Park SM; Casey RT
    Clin Endocrinol (Oxf); 2020 Oct; 93(4):409-418. PubMed ID: 32430905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experiences of individuals with a variant of uncertain significance on genetic testing for hereditary cancer risks: a mixed method systematic review.
    Gould D; Walker R; Makari-Judson G; Seven M
    J Community Genet; 2022 Aug; 13(4):371-379. PubMed ID: 35819584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
    Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
    Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.